Post‐marketing analysis for biosimilar CT‐P13 in inflammatory bowel disease compared with external data of originator infliximab in Japan

por Sagami, Shintaro, Nishikawa, Kiyohiro, Yamada, Fumika, Suzuki, Yasuo, Watanabe, Mamoru, Hibi, Toshifumi
Publicado 2021

Safety, efficacy, and drug survival of the infliximab biosimilar CT‐P13 in post‐marketing surveillance of Japanese patients with psoriasis

por Morita, Akimichi, Nishikawa, Kiyohiro, Yamada, Fumika, Yamanaka, Keiichi, Nakajima, Hideki, Ohtsuki, Mamitaro
Publicado 2022

Real-World Safety and Efficacy of Biosimilar CT-P13 in Patients with Immune-Mediated Inflammatory Diseases: Integrated Analysis of Three Japanese Prospective Observational Studies

por Takeuchi, Tsutomu, Nishikawa, Kiyohiro, Yamada, Fumika, Morita, Akimichi, Ohtsuki, Mamitaro, Suzuki, Yasuo, Watanabe, Mamoru, Yamanaka, Hisashi, Hibi, Toshifumi
Publicado 2023

Infliximab biosimilar CT-P13 is interchangeable with its originator for patients with inflammatory bowel disease in real world practice

por Nakagawa, Tomoo, Kobayashi, Taku, Nishikawa, Kiyohiro, Yamada, Fumika, Asai, Satoshi, Sameshima, Yukinori, Suzuki, Yasuo, Watanabe, Mamoru, Hibi, Toshifumi
Publicado 2019